GB0901423D0 - Treatment - Google Patents

Treatment

Info

Publication number
GB0901423D0
GB0901423D0 GBGB0901423.4A GB0901423A GB0901423D0 GB 0901423 D0 GB0901423 D0 GB 0901423D0 GB 0901423 A GB0901423 A GB 0901423A GB 0901423 D0 GB0901423 D0 GB 0901423D0
Authority
GB
United Kingdom
Prior art keywords
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0901423.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SECR DEFENCE
UK Secretary of State for Defence
Original Assignee
SECR DEFENCE
UK Secretary of State for Defence
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SECR DEFENCE, UK Secretary of State for Defence filed Critical SECR DEFENCE
Priority to GBGB0901423.4A priority Critical patent/GB0901423D0/en
Publication of GB0901423D0 publication Critical patent/GB0901423D0/en
Priority to GB1001517A priority patent/GB2467436A/en
Priority to PCT/GB2010/000146 priority patent/WO2010086614A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB0901423.4A 2009-01-29 2009-01-29 Treatment Ceased GB0901423D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB0901423.4A GB0901423D0 (en) 2009-01-29 2009-01-29 Treatment
GB1001517A GB2467436A (en) 2009-01-29 2010-01-29 Phosphoantigen for use in treatment of Burkholderia infection
PCT/GB2010/000146 WO2010086614A1 (en) 2009-01-29 2010-01-29 Treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0901423.4A GB0901423D0 (en) 2009-01-29 2009-01-29 Treatment

Publications (1)

Publication Number Publication Date
GB0901423D0 true GB0901423D0 (en) 2009-03-11

Family

ID=40469227

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB0901423.4A Ceased GB0901423D0 (en) 2009-01-29 2009-01-29 Treatment
GB1001517A Withdrawn GB2467436A (en) 2009-01-29 2010-01-29 Phosphoantigen for use in treatment of Burkholderia infection

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB1001517A Withdrawn GB2467436A (en) 2009-01-29 2010-01-29 Phosphoantigen for use in treatment of Burkholderia infection

Country Status (2)

Country Link
GB (2) GB0901423D0 (en)
WO (1) WO2010086614A1 (en)

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
SE8205892D0 (en) 1982-10-18 1982-10-18 Bror Morein IMMUNOGENT MEMBRANE PROTEIN COMPLEX, SET FOR PREPARATION AND USE THEREOF
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0362278A4 (en) 1987-06-05 1990-05-14 Us Health AUTOCRINE MOBILITY FACTORS IN DIAGNOSTIC AND TREATMENT OF CANCER.
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5308854A (en) 1990-06-18 1994-05-03 Merck & Co., Inc. Inhibitors of HIV reverse transcriptase
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5187074A (en) 1990-10-11 1993-02-16 Merck & Co., Inc. Method of hydroxylation with ATCC 55086
US5192668A (en) 1990-10-11 1993-03-09 Merck & Co., Inc. Synthesis of protease inhibitor
WO1993008184A1 (en) 1991-10-23 1993-04-29 Merck & Co., Inc. Hiv protease inhibitors
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
UA40597C2 (en) 1992-06-25 2001-08-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition, method for treatment of mammals, diseased or receptive to the infection, method for treatment of mammals with cancer, method for production of vaccine composition, composition of adjuvants
US5663169A (en) 1992-08-07 1997-09-02 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
EP1175912A1 (en) 1993-03-23 2002-01-30 SmithKline Beecham Biologics SA Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
AU7973994A (en) 1993-10-13 1995-05-04 Merck & Co., Inc. Combination therapy for hiv infection
JP3967769B2 (en) 1993-11-17 2007-08-29 オーエム・ファルマ Glucosamine disaccharides, process for their production, pharmaceutical compositions containing them and their use
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US5476874A (en) 1994-06-22 1995-12-19 Merck & Co., Inc. New HIV protease inhibitors
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
UA56132C2 (en) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
EP0761819A1 (en) * 1995-09-12 1997-03-12 BEHRINGWERKE Aktiengesellschaft Exopolysaccharides of burkholderia pseudomallei and burkholderia mallei
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US5846978A (en) 1996-05-02 1998-12-08 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
WO1999064301A1 (en) 1998-06-08 1999-12-16 Sca Emballage France Fast flattening packaging
CN1168702C (en) 1998-06-30 2004-09-29 Om药业 Movel acyl pseudodipeoptides, prepn method and pharmaceutical compsns. contg. same
FR2782721B1 (en) 1998-09-01 2000-11-03 Inst Nat Sante Rech Med NOVEL PHOSPHOHALOHYDRIN COMPOUNDS, MANUFACTURING METHOD AND APPLICATIONS
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
EP1187629B1 (en) 1999-04-19 2004-09-22 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
WO2001046127A1 (en) 1999-12-22 2001-06-28 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
CA2453817C (en) * 2001-07-20 2011-09-20 Bioagency Ag Organophosphorus compounds for the activation of gamma/delta t-cells
US20070025960A1 (en) * 2003-05-16 2007-02-01 University Of Maryland Biotechnology Institute Bisphosphonates for prophylaxis and therapy against bioterrorism agents
WO2006067635A2 (en) * 2004-12-20 2006-06-29 Innate Pharma S.A. USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT
EP1863572A2 (en) 2005-03-22 2007-12-12 Innate Pharma New class of t cells activators and use thereof
GB0519871D0 (en) * 2005-09-30 2005-11-09 Secr Defence Immunogenic agents
GB0615635D0 (en) * 2006-08-07 2006-09-13 Secr Defence Immunogenic proteins and uses thereof
EP2087128A4 (en) * 2006-11-01 2009-11-04 Immport Therapeutics Inc COMPOSITION AND METHODS FOR IMMUNODOMINANT ANTIGENS
WO2008146167A2 (en) * 2007-06-01 2008-12-04 Innate Pharma S.A. Improved methods of using phosphoantigens together with interleukin-2 for the treatment of cancer
EP2123285A1 (en) * 2008-05-21 2009-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Nucleosidic phosphoantigens for use in VGAMMA9DELTA2 T cell-mediated therapy

Also Published As

Publication number Publication date
GB2467436A (en) 2010-08-04
GB201001517D0 (en) 2010-03-17
WO2010086614A1 (en) 2010-08-05

Similar Documents

Publication Publication Date Title
GB0823213D0 (en) Treatment
PL2652193T3 (en) Treatment
GB0802116D0 (en) Treatment
GB0920112D0 (en) Treatment device
GB0822011D0 (en) Treatment
IL217492A0 (en) Treatment method
IL214133A0 (en) Skin treatment
LT2745837T (en) Glomerulonephritis Treatment
GB0811992D0 (en) Treatment
GB0900599D0 (en) Treatment
GB201013898D0 (en) Well treatment
GB201013573D0 (en) Treatment
GB0913968D0 (en) Treatment
GB201001521D0 (en) Treatment
PL2263454T3 (en) Treatment composition
GB0916997D0 (en) Combination therapy
GB0820972D0 (en) Treatment
GB0805912D0 (en) Treatment
GB0907973D0 (en) Combination therapy
GB201014097D0 (en) Treatment
GB0901423D0 (en) Treatment
GB0914581D0 (en) Well treatment
GB0916542D0 (en) Well treatment
GB0915045D0 (en) Treatment system
GB0921244D0 (en) Therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)